Maryland HB484 modifies the corporate income tax to allow deductions for direct-to-consumer advertising expenses of covered drugs.

Maryland HB484 amends the corporate income tax to permit deductions for direct-to-consumer advertising expenses of covered drugs, which are prescription drugs or compounded drugs. These expenses can be deducted under the Internal Revenue Code. The bill defines "direct-to-consumer advertising" as any advertisement targeting the general public through various media, including broadcast, mail, and digital platforms. The changes apply to taxable years beginning after December 31, 2025.

Maryland HB484 modifies the corporate income tax to allow deductions for direct-to-consumer advertising expenses of covered drugs.

Maryland HB484 amends the corporate income tax to permit deductions for direct-to-consumer advertising expenses of covered drugs, which are prescription drugs or compounded drugs. These expenses can be deducted under the Internal Revenue Code. The bill defines "direct-to-consumer advertising" as any advertisement targeting the general public through various media, including broadcast, mail, and digital platforms. The changes apply to taxable years beginning after December 31, 2025.